Topics in lipoprotein glomerulopathy: an overview.

Area of Science:

• Nephrology
• Genetics
• Biochemistry

Background:

• Lipoprotein glomerulopathy (LPG) is a rare kidney disease with around 150 reported cases globally.
• Specific apolipoprotein E (APOE) variants, APOE-Sendai and APOE-Kyoto, are linked to LPG and suggest a founder effect origin in Japan and China.
• APOE variants induce abnormal lipoprotein aggregation, leading to thrombi formation within the glomerulus.

Purpose of the Study:

• To explore key aspects of lipoprotein glomerulopathy (LPG).
• To investigate the genetic and molecular mechanisms underlying LPG.
• To identify potential therapeutic strategies for managing LPG and preventing renal dysfunction.

Main Methods:

• Review and synthesis of existing literature on LPG.
• Analysis of genetic variations in apolipoprotein E (APOE) associated with LPG.
• Examination of lipoprotein metabolism and macrophage function in the context of LPG.

Main Results:

• APOE-Sendai and APOE-Kyoto variants, prevalent in specific regions, likely arose from a founder effect.
• These variants alter apolipoprotein structure, promoting lipoprotein aggregation and glomerular thrombi.
• Macrophage dysfunction may contribute to lipoprotein accumulation in the glomerulus, independent of foam cell formation.

Conclusions:

• Lipoprotein glomerulopathy pathogenesis involves specific APOE variants and potential macrophage impairment.
• Early intervention with fibrates and intensive management of triglyceride and APOE levels are crucial for ameliorating LPG and preserving kidney function.